KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Non Operating Income: 2018-2024

Historic Other Non Operating Income for Acadia Pharmaceuticals (ACAD) over the last 7 years, with Dec 2024 value amounting to $1.8 million.

  • Acadia Pharmaceuticals' Other Non Operating Income rose 2.95% to $593,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 14.73%. This contributed to the annual value of $1.8 million for FY2024, which is 64.32% down from last year.
  • Acadia Pharmaceuticals' Other Non Operating Income amounted to $1.8 million in FY2024, which was down 64.32% from $5.1 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Other Non Operating Income ranged from a high of $5.1 million in FY2023 and a low of -$997,000 during FY2020.
  • For the 3-year period, Acadia Pharmaceuticals' Other Non Operating Income averaged around $3.5 million, with its median value being $3.5 million (2022).
  • Its Other Non Operating Income has fluctuated over the past 5 years, first plummeted by 200.00% in 2020, then surged by 333.60% in 2021.
  • Acadia Pharmaceuticals' Other Non Operating Income (Yearly) stood at -$997,000 in 2020, then surged by 333.60% to $2.3 million in 2021, then spiked by 52.08% to $3.5 million in 2022, then spiked by 44.24% to $5.1 million in 2023, then slumped by 64.32% to $1.8 million in 2024.